Iptakalim protects against MPP+-induced degeneration of dopaminergic neurons in association with astrocyte activation

International Journal of Neuropsychopharmacology

Volumn 12, Issue 3, 2009, Pages 317-327

  Yang, Yan Jing ^a   Zhang, Shu ^a   Ding, Jian Hua ^a   Zhou, Fang ^a   Hu, Gang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Astrocyte activation; ATP sensitive potassium channel opener; Iptakalim; Parkinson's disease; TNF

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 5 HYDROXYDECANOIC ACID; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; DIAZOXIDE; IPTAKALIM; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA; 5-HYDROXYDECANOIC ACID; DECANOIC ACID DERIVATIVE; DOPAMINE; ECTODYSPLASIN A; GLIAL FIBRILLARY ACIDIC PROTEIN; HYDROXYACID; N (1 METHYLETHYL) 1,1,2 TRIMETHYLPROPYLAMINE; N-(1-METHYLETHYL)-1,1,2-TRIMETHYLPROPYLAMINE; NEUROPROTECTIVE AGENT; POTASSIUM CHANNEL BLOCKING AGENT; PROPYLAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; MALE; MICROGLIA; MOTOR COORDINATION; MOTOR PERFORMANCE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; ROTAROD TEST; ANALYSIS OF VARIANCE; ANIMAL; BRAIN STEM; CELL CULTURE; CELL DEATH; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; INTOXICATION; METABOLISM; METHODOLOGY; MOTOR ACTIVITY; NERVE CELL; NERVE DEGENERATION; NEWBORN; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYLPYRIDINIUM; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; BRAIN STEM; CELL DEATH; CELLS, CULTURED; DECANOIC ACIDS; DIAZOXIDE; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ECTODYSPLASINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HYDROXY ACIDS; MALE; MOTOR ACTIVITY; MPTP POISONING; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; POTASSIUM CHANNEL BLOCKERS; PROPYLAMINES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE 3-MONOOXYGENASE;

EID: 66449135704     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708009243     Document Type: Article

References (53)

1. Ardehali H, O'Rourke B (2005). Mitochondrial K(ATP) channels in cell survival and death. Journal of Molecular and Cellular Cardiology 39, 7-16. (Pubitemid 40836042)
2. Aschner M (1998). Astrocytes as mediators of immune and inflammatory responses in the CNS. Neurotoxicology 19, 269-281.
3. Bajgar R, Seetharaman S, Kowaltowski AJ, Garlid KD, Paucek P (2001). Identification and properties of a novel intracellular (mitochondrial) ATP-sensitive potassium channel in brain. Journal of Biological Chemistry 276, 33369-33374.
4. 2+ accumulation in CA1 pyramidal cells after cerebral ischemia in newborn pigs. Brain Research 1019, 97-104.
5. + channel in rat brain. Brain Research 814, 41-54.
6. Forno LS, DeLanney LE, Irwin I, Di Monte D, Langston JW (1992). Astrocytes and Parkinson's disease. Progress in Brain Research 94, 429-436.
7. Hansen JB (2006). Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives. Current Medicinal Chemistry 13, 361-376.
8. Hirsch EC (2000). Glial cells and Parkinson's disease. Journal of Neurology 247 (Suppl. 2), 58-62.
9. + on SH-SY5Y cells by decreasing extracellular glutamate level. Journal of Neurochemistry 94, 1570-1579.
10. Ikeda H, Murase K (2004). Glial nitric oxide-mediated long-term presynaptic facilitation revealed by optical imaging in rat spinal dorsal horn. Journal of Neuroscience 24, 9888-9896.
11. Kis B, Rajapakse NC, Snipes JA, Nagy K, Horiguchi T, Busija DW (2003). Diazoxide induces delayed pre-conditioning in cultured rat cortical neurons. Journal of Neurochemistry 87, 969-980.
12. Kruger NJ (1994). The Bradford method for protein quantitation. Methods in Molecular Biology 32, 9-15.
13. Kumar S, Boehm J, Lee JC (2003). P38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nature Reviews Drug Discovery 2, 717-726.
14. + channel in the brain. Brain Research 994, 27-36.
15. Lau LT, Yu AC (2001). Astrocytes produce and release interleukin-1, interleukin-6, tumor necrosis factor alpha and interferon-gamma following traumatic and metabolic injury. Journal of Neurotrauma 18, 351-359.
16. Liberatore GT, Jackson-Lewis V, Vukosavic S (1999). Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nature Medicine 5, 1403-1409.
17. Liss B, Haeckel O, Wildmann J, Miki T, Seino S, Roeper J (2005). K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nature Medicine 8, 1742-1751.
18. Liu B, Gao HM, Wang JY, Jeohn GH, Cooper CL, Hong JS (2002). Role of nitric oxide in inflammation-mediated neurodegeneration. Annals of the New York Academy of Sciences 962, 318-331.
19. Lu X, Bing G, Hagg T (2000). Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats. Neuroscience 97, 285-291.
20. Marchetti B, Abbracchio MP (2005). To be or not to be (inflamed) - is that the question in anti-inflammatory drug therapy of neurodegenerative disorders? Trends in Pharmacological Sciences 26, 517-525.
21. Minghetti L (2005). Role of inflammation in neuro-degenerative diseases. Current Opinion in Neurology 18, 315-321.
22. Mirza B, Hadberg H, Thomsen P, Moos T (2000). The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 95, 425-432.
23. Nakagawa I, Alessandri B, Heimann A, Kempski O (2005). MitoKATP-channel opener protects against neuronal death in rat venous ischemia. Neurosurgery 57, 334-340.
24. Paxinos G, Watson C (1997). The Rat Brain in Stereotaxic Coordinates, 3rd edn. San Diego: Academic Press.
25. Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S (2000). The parkinsonian toxin MPTP: action and mechanism. Restorative Neurology and Neuroscience 16, 135-142.
26. Rajapakse N, Kis B, Horiguchi T, Snipes J, Busija D (2003). Diazoxide pretreatment induces delayed preconditioning in astrocytes against oxygen glucose deprivation and hydrogen peroxide-induced toxicity. Journal of Neuroscience Research 73, 206-214.
27. Rozas G, Lopez-Martin E, Guerra MJ, Labandeira-Garcia JL (1998). The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. Journal of Neuroscience Methods 83, 165-175.
28. Saklatvala J (2004). The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Current Opinion in Ppharmacology 4, 372-377.
29. Seifert G, Schilling K, Steinhauser C (2006). Astrocyte dysfunction in neurological disorders: a molecular perspective. Nature Reviews Neuroscience 7, 194-206.
30. Smeyne M, Jiao Y, Shepherd KR, Smeyne RJ (2005). Glia cell number modulates sensitivity to MPTP in mice. Glia 52, 144-152.
31. Tai KK, McCrossan ZA, Abbott GW (2003). Activation of mitochondrial ATP-sensitive potassium channels increases cell viability against rotenone-induced cell death. Journal of Neurochemistry 84, 1193-1200.
32. Tateishi N, Mori T, Kagamiishi Y, Satoh S, Katsube N, Morikawa E (2002). Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. Journal of Cerebral Blood Flow and Metabolism 22, 723-734.
33. Teismann P, Tieu K, Cohen O, Choi DK, Wu DC, Marks D (2003). Pathogenic role of glial cells in Parkinson's disease. Movement Disorders 18, 121-129.
34. Teshima Y, Akao M, Li RA, Chong TH, Baumgartner WA, Johnston MV, Marban E (2003). Mitochondrial ATP-sensitive potassium channel activation protects cerebellar granule neurons from apoptosis induced by oxidative stress. Stroke 34, 1796-1802.
35. Tipton KF, Singer TP (1993). Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. Journal of Neurochemistry 61, 1191-1206.
36. Vila M, Jackson-Lewis V, Guegan C, Wu DC, Teismann P (2001). The role of glial cells in Parkinson's disease. Current Opinion in Neurology 14, 483-489.
37. Volterra A, Meldolesi J (2005). Astrocytes, from brain glue to communication elements: the revolution continues. Nature Reviews Neuroscience 6, 626-640.
38. + channel as a new molecular target for development of antihypertensive drugs. Acta Pharmacologica Sinica 19, 397-402.
39. Wang H (2003). Pharmacological characteristics of the novel antihypertensive drug, iptakalim hydrochloride, and its molecular mechanisms. Drug Development Research 58, 65-68.
40. Wang H, Zhang YL, Tang XC, Feng HS, Hu G (2004). Targeting ischemic stroke with a novel opener of ATP-sensitive potassium channels in the brain. Molecular Pharmacology 66, 1160-1168.
41. Wang S, Hu LF, Yang Y, Ding JH, Hu G (2005). Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson's disease: implications for treating Parkinson's disease? Neuropharmacology 48, 984-992.
42. Wang S, Hu LF, Zhang Y, Sun T, Sun YH, Liu SY, Ding JH, Wu J, Hu G (2006). Effects of systemic administration of iptakalim on extracellular neurotransmitter levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats. Neuropsychopharmacology 31, 933-940.
43. Watanabe Y, Himeda T, Araki T (2005). Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease. Medicine Science Monitor 11, 17-23.
44. West MJ (1993). New stereological methods for counting neurons. Neurobiology Aging 14, 275-285.
45. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C (2002). Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine mouse model of Parkinson disease. Journal of Neuroscience 22, 1763-1771.
46. Wu J, Wakui M, Wang H, Hu G (2005). Iptakalim hydrochloride and neuronal protection. Current Neuropharmacology 3, 1-9.
47. Xie W, Wang H, Ding J, Wang H, Hu G (2005). Anti-proliferating effect of iptakalim, a novel KATP channel opener, in cultured rabbit pulmonary arterial smooth muscle cells. European Journal of Pharmacology 511, 81-87.
48. Yang J, Hu LF, Liu X, Zhou F, Ding JH, Hu G (2006a). Effects of iptakalim on extracellular glutamate and dopamine levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Life Sciences 78, 1940-1944.
49. Yang Y, Liu X, Ding JH, Sun J, Long Y, Wang F, Yao HH, Hu G (2004). Effects of iptakalim on rotenone-induced cytotoxicity and dopamine release from PC12 cells. Neuroscience Letters 366, 53-57. (Pubitemid 38953147)
50. Yang Y, Liu X, Long Y, Wang F, Ding JH, Liu SY, Sun YH, Yao HH, Wang H, Wu J, Hu G (2005). Systematic administration of iptakalim, an ATP-sensitive potassium channel opener, prevents rotenone-induced motor and neurochemical alterations in rats. Journal of Neuroscience Research 80, 442-449.
51. Yang Y, Liu X, Long Y, Wang F, Ding JH, Liu SY, Sun YH, Yao HH, Wang H, Wu J, Hu G (2006b). Activation of mitochondrial ATP-sensitive potassium channels improves rotenone-related motor and neurochemical alterations in rats. International Journal of Neuro-psychopharmacology 9, 51-61.
52. +-induced astrocytic apoptosis via mitochondria and MAPK signal pathways. Journal of Neurochemistry 103, 569-579.
53. Zhou F, Wu JY, Sun XL, Yao HH, Ding JH, Hu G (2007). Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia-mediated neuroinflammation. Neuropsychopharmacology 32, 2570-2580.